Evidence map›Paper›PMID 41507151›Full record

ArticleNature communications2026

SOX2 confers tumour permissiveness in a specific skin progenitor population.

Patricia P Centeno, Christopher Chester, Georgios Kanellos, Catriona A Ford, Patrizia Cammareri, Gareth J Inman, Thomas Jamieson, Rachel A Ridgway, Richard Marais, Andrew D Campbell and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Patricia P CentenoCancer Research UK Scotland Institute, Glasgow, UK. P.Centeno@crukscotlandinstitute.ac.uk.ORCID http://orcid.org/0000-0002-8754-7812
Christopher ChesterCancer Research UK Manchester Institute, Manchester, UK.
Georgios KanellosCancer Research UK Scotland Institute, Glasgow, UK.ORCID http://orcid.org/0000-0002-2467-4523
Catriona A FordCancer Research UK Scotland Institute, Glasgow, UK.
Patrizia CammareriCancer Research UK Scotland Institute, Glasgow, UK.
Gareth J InmanCancer Research UK Scotland Institute, Glasgow, UK.ORCID http://orcid.org/0000-0002-6264-4253
Thomas JamiesonCancer Research UK Scotland Institute, Glasgow, UK.
Rachel A RidgwayCancer Research UK Scotland Institute, Glasgow, UK.
Richard MaraisCancer Research UK Manchester Institute, Manchester, UK.ORCID http://orcid.org/0000-0001-7484-4183
Andrew D CampbellCancer Research UK Scotland Institute, Glasgow, UK.ORCID http://orcid.org/0000-0003-3930-1276
Owen J SansomCancer Research UK Scotland Institute, Glasgow, UK. owen.sansom@glasgow.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The continuous renewal of the skin relies on stem and progenitor cells, yet their differential susceptibility to oncogenic mutations in cutaneous squamous cell carcinoma (cSCC) remains unclear. Rapid cSCC develops in melanoma patients on BRAF inhibitors due to paradoxical MAPK activation. To model this in mice, we use two complementary approaches: HRAS

Indexed as

Carcinoma, Squamous CellSkinSkin NeoplasmsSOXB1 Transcription FactorsStem CellsAnimalsCell Transformation, NeoplasticCutaneous Squamous Cell CarcinomaFemaleGene Expression Regulation, NeoplasticHumansMelanomaMiceMutationNeoplastic Stem CellsProto-Oncogene Proteins B-rafProto-Oncogene Proteins B-rafSOX2 protein, humanSox2 protein, mouseSOXB1 Transcription Factors

Identifiers

PMID41507151
PMCPMC12789432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.